Generic Atelvia Availability

Atelvia is a brand name of risedronate, approved by the FDA in the following formulation(s):

ATELVIA (risedronate sodium - tablet, delayed release;oral)

Has a generic version of Atelvia been approved?

No. There is currently no therapeutically equivalent version of Atelvia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atelvia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical compositions containing geminal diphosphonates
    Patent 5,583,122
    Issued: December 10, 1996
    Inventor(s): Benedict; James J. & Perkins; Christopher M.
    Assignee(s): The Procter & Gamble Company
    Pharmaceutical compositions, useful for treating abnormal calcium and phosphate metabolism, which contain geminal-diphosphonic acid compounds; and a method of treating diseases characterized by abnormal calcium and phosphate metabolism utilizing these pharmaceutical compositions.
    Patent expiration dates:
    • December 10, 2013
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 10, 2014
      ✓ 
      Pediatric exclusivity
  • Dosage forms of risedronate
    Patent 5,622,721
    Issued: April 22, 1997
    Inventor(s): Dansereau; Richard J. & Mosher; Russell Y. & Axelrod; Douglas W. & Sietsema; William K.
    Assignee(s): The Procter & Gamble Company
    The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical composition which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower gastrointestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which occasionally accompanies the oral administration of risedronate active ingredients.
    Patent expiration dates:
    • April 21, 2014
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Dosage forms of bisphosphonates
    Patent 7,645,459
    Issued: January 12, 2010
    Inventor(s): Dansereau; Richard John & Burgio, Jr.; David Ernest
    Assignee(s): The Procter & Gamble Company
    Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
    Patent expiration dates:
    • January 9, 2028
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Dosage forms of risedronate
    Patent 7,645,460
    Issued: January 12, 2010
    Inventor(s): Dansereau; Richard John & Burgio, Jr.; David Ernest
    Assignee(s): The Procter & Gamble Company
    Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
    Patent expiration dates:
    • January 9, 2028
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Dosage forms of bisphosphonates
    Patent 8,246,989
    Issued: August 21, 2012
    Inventor(s): Dansereau; Richard John & Burgio, Jr.; David Ernest
    Assignee(s): Warner Chilcott Company, LLC
    Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
    Patent expiration dates:
    • January 16, 2026
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 8, 2013 - NEW DOSAGE FORM

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)